Skip to content

Rumination as a predictor of relapse in mindfulness-based cognitive therapy for depression.

Johannes Michalak, Anne Hölz, Tobias Teismann

Psychology and Psychotherapy Theory Research and Practice June 2011 DOI: 10.1348/147608310x520166 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Uncontrolled study Peer reviewed
Sample size 24
Population Formerly depressed patients
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 12-month follow-up after end of MBCT
Measures Ruminative Response Scale, Structured Clinical Interview for DSM-IV
Topics Depression Meditation
Key points Rumination significantly decreased during MBCT, and post-treatment rumination levels predicted relapse risk over 12 months, even after controlling for previous episodes and residual symptoms. The authors propose this as preliminary evidence that rumination plays a role in depressive relapse.

Abstract

In mindfulness-based cognitive therapy (MBCT), it is proposed that training in mindfulness should reduce the tendency of formerly depressed patients to enter into ruminative thinking, thus reducing their risk of depressive relapse. However, data showing that rumination is associated with depressive relapse are lacking. In an uncontrolled study with 24 formerly depressed patients, rumination was assessed with the Ruminative Response Scale. To assess the occurrence of relapse or recurrence, the Structured Clinical Interview for DSM-IV was administered 12 months after the end of the MBCT. Rumination significantly decreased during the MBCT course. Post-treatment levels of rumination predicted the risk of relapse of major depressive disorder in the 12-month follow-up period even after controlling for numbers of previous episodes and residual depressive symptoms. The results provide preliminary evidence that rumination is important in the process of depressive relapse.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 37

and 32 more in the library

Cites 10

and 5 more in the library

Explore topics